Silk Road Medical Q1 2024 GAAP EPS $(0.36) Beats $(0.40) Estimate, Sales $48.484M Beat $44.676M Estimate
Silk Road Medical Q1 2024 GAAP EPS $(0.36) Beats $(0.40) Estimate, Sales $48.484M Beat $44.676M Estimate
絲路醫療2024年第一季度GAAP每股收益美元（0.36美元）超過預期（0.40美元），銷售額爲4,8484萬美元超過4,4676萬美元的預期
Silk Road Medical (NASDAQ:SILK) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.40) by 10 percent. This is a 16.28 percent increase over losses of $(0.43) per share from the same period last year. The company reported quarterly sales of $48.484 million which beat the analyst consensus estimate of $44.676 million by 8.52 percent. This is a 20.81 percent increase over sales of $40.131 million the same period last year.
絲路醫療（納斯達克股票代碼：SILK）公佈的季度虧損爲每股0.36美元，比分析師普遍預期的0.40美元（0.40美元）高出10％。這比去年同期每股虧損0.43美元（0.43美元）增長了16.28％。該公司公佈的季度銷售額爲4,848.4萬美元，比分析師普遍預期的4,467.6萬美元高出8.52％。這比去年同期的4,013.1萬美元銷售額增長了20.81％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。